AbCellera Biologics announced the successful completion of the first phase of its collaboration with Denali Therapeutics. Under the collaboration, AbCellera applied its single-cell screening technology to discover hundreds of novel monoclonal antibodies with specific binding properties against a genetically-validated target for neurodegenerative disease. Denali’s CEO, Ryan Watts, Ph.D., commented, “We are thrilled to collaborate with AbCellera…